Lupin’s US business to stay above $1 billion; biosimilars and specialty portfolio to drive growth
Published on: May 8, 2026, 3:48 p.m. | Source: CNBC TV18
Ramesh Swaminathan, ED & Global CFO at Lupin, said the company expects margins to remain around 25% for the full year, supported by strong performance from products such as Tolvaptan and Mirabegron. However, he noted that rising freight costs and the possibility of future competition in key US products could create some pressure on margins.
